Local Treatment Options for Unresectable Liver Metastases in Colorectal Cancer

Despite the increase in effectiveness of systemic therapy, cure for colorectal cancer with liver metastases (CRLM) is rarely achieved without surgical resection, with less than 20% of patients initially suitable for surgery. Liver-directed therapies are continually being investigated in the hope of improving cure rates in patients with unresectable liver metastases. These modalities include selective internal radiation therapy (SIRT), radiofrequency ablation (RFA), transarterial chemoembolization (TACE) and hepatic artery infusion (HAI) chemotherapy. While there is evidence of activity for all these treatments, they are somewhat lacking in high level randomized, controlled trial evidence (RCT) with appropriate control arms relevant to current standard of care. This review examines the efficacy and safety of these treatments in unresectable CRLM

Correlación entre los cubtipos moleculares intrínsecos en el cáncer de mama por PAM50 y la inmunohistoquímica tumoral

Tesis inédita de la Universidad Complutense de Madrid, Facultad de Medicina, Departamento de Medicina, leída el 24-06-2013Depto. de MedicinaFac. de MedicinaTRUEunpu

Outcomes in rare cancer patients who underwent comprehensive genomic sequencing in the NOMINATOR study

Aims: Rare cancers (RCs) are difficult to research and consequently often lack evidence-based treatments. Identifying underlying genomic biomarkers may allow more rational selection of treatments or clinical trials. We report treatment and survival in RC patients (pts) following next-generation sequencing (NGS) in the NOMINATOR study (ACTRN12616001000493).Methods: Pts with rare histology, poor-prognosis solid-tumours, and limited treatment options underwent NGS (PMCC panel; 391 genes) of paired tumour:blood DNA. Virtual molecular tumour board review of clinical history, pathology and genomic results for actionability (OncoKB) provided treatment recommendations. Pts were followed for up to 2 years for impact on treatment and outcomes.Results: 121 pts were prospectively enrolled between July 2017 to Nov 2019 and 100 tumours successfully sequenced. 56 (56%) had potentially actionable results: 27 matched to a clinically validated drug; and 29 a biologically plausible treatment. As of August 2020, of 94 pt with advanced-stage disease (and excluding hormonal therapies), 13 started one or more lines of genomically-matched therapy; 57 an unmatched therapy; and 24 received no further treatment. Pts were more likely to access a matched therapy for approved indications (5/5) or with stronger evidence (OncoKB 2, 5/12). Drug access was provided by the government (PBS) (4), self-funded (3), pharma (3) or clinical trial (4). Median OS (mOS) from consent for pts receiving matched, unmatched, and no treatment was 20.9 (n = 13), 16.5 (57) and 20.1 (24) months, respectively. The corresponding mOS from advanced disease was 27.3, 31.0 and 33.8 months. 8 pts died prior to or within 28 days of NGS result availability.Conclusions: NGS in RCs was feasible and identified potentially actionable results in half of cases. OS was similar across treatment groups explored, although heterogeneity in RC type and prior treatments limit analysis. Earlier testing and improved drug/trial access, including combination therapies, may improve likelihood of benefit from NGS